Brief: Biofrontera Inc. Announces FDA Orange Book Listing Of U.S. Patent For BF-RhodoLED® XL, Extends Protection Of Ameluz®-PDT Through October 2040
14/03/2022 14:21
March 14 (Reuters) - Biofrontera Inc BFRI.O :
* BIOFRONTERA INC. ANNOUNCES FDA ORANGE BOOK LISTING OF U.S.
PATENT FOR BF-RHODOLED® XL, EXTENDS PROTECTION OF AMELUZ®-PDT
THROUGH OCTOBER 2040
Source text for Eikon: ID:nGNX3S23tT
Further company coverage: BFRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales